Xu L, Sanchez A, Yang Z, Zaki S R, Nabel E G, Nichol S T, Nabel G J
Department of Biological Chemistry, University of Michigan Medical Center, Ann Arbor 48109-0650, USA.
Nat Med. 1998 Jan;4(1):37-42. doi: 10.1038/nm0198-037.
Infection by Ebola virus causes rapidly progressive, often fatal, symptoms of fever, hemorrhage and hypotension. Previous attempts to elicit protective immunity for this disease have not met with success. We report here that protection against the lethal effects of Ebola virus can be achieved in an animal model by immunizing with plasmids encoding viral proteins. We analyzed immune responses to the viral nucleoprotein (NP) and the secreted or transmembrane forms of the glycoprotein (sGP or GP) and their ability to protect against infection in a guinea pig infection model analogous to the human disease. Protection was achieved and correlated with antibody titer and antigen-specific T-cell responses to sGP or GP. Immunity to Ebola virus can therefore be developed through genetic vaccination and may facilitate efforts to limit the spread of this disease.
埃博拉病毒感染会引发迅速进展且往往致命的症状，包括发热、出血和低血压。此前为该疾病诱导保护性免疫的尝试均未成功。我们在此报告，在动物模型中，通过用编码病毒蛋白的质粒进行免疫接种，可以实现对埃博拉病毒致死效应的保护。我们分析了对病毒核蛋白（NP）以及糖蛋白的分泌型或跨膜型（sGP或GP）的免疫反应，以及它们在类似于人类疾病的豚鼠感染模型中预防感染的能力。实现了保护作用，且与抗体滴度以及针对sGP或GP的抗原特异性T细胞反应相关。因此，通过基因疫苗接种可以产生对埃博拉病毒的免疫力，这可能有助于限制该疾病的传播。
